Related references
Note: Only part of the references are listed.The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin
Rakesh K. Pathak et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells
Qinqin Cheng et al.
CHEMICAL COMMUNICATIONS (2014)
Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
Yao-Rong Zheng et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Crystal structure of the human glucose transporter GLUT1
Dong Deng et al.
NATURE (2014)
Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties
Pengxing Liu et al.
CHEMICAL COMMUNICATIONS (2013)
Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity
William D. Figg et al.
CLINICAL GENITOURINARY CANCER (2013)
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer
Jeremy Cetnar et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Clinical and pharmacokinetic evaluation of satraplatin
Gury Doshi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
What do we know about the reduction of Pt(IV) pro-drugs?
Ezequiel Wexselblatt et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
Pt(IV) complexes as prodrugs for cisplatin
Yi Shi et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2012)
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies
Elisa Gallerani et al.
ACTA ONCOLOGICA (2011)
Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21waf1/cip1-independent pathway in human colorectal cancer cells
Murugan Kalimutho et al.
ACTA PHARMACOLOGICA SINICA (2011)
Drug transporters of platinum-based anticancer agents and their clinical significance
Herman Burger et al.
DRUG RESISTANCE UPDATES (2011)
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes
Michael R. Reithofer et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2011)
Dysregulated pH: a perfect storm for cancer progression
Bradley A. Webb et al.
NATURE REVIEWS CANCER (2011)
Different Features of the DNA Binding Mode of Antitumor cis-Amminedichlorido(cyclohexylamine)platinum(H) (JM118) and Cisplatin in Vitro
Hana Kostrhunova et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2010)
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate et al.
DALTON TRANSACTIONS (2010)
Mechanisms of Cisplatin Nephrotoxicity
Ronald P. Miller et al.
TOXINS (2010)
Satraplatin: leading the new generation of oral platinum agents
Ashish Bhargava et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Current status and future prospects for satraplatin, an oral platinum analogue
Hak Choy et al.
CLINICAL CANCER RESEARCH (2008)
Tumor cell metabolism imaging
Christian Plathow et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles
Shanta Dhar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth
Sebastien Bonnet et al.
CANCER CELL (2007)
Acid-mediated tumor invasion: a multidisciplinary study
RA Gatenby et al.
CANCER RESEARCH (2006)
Platinum group antitumor chemistry: Design and development of new anticancer drugs complementary to cisplatin
AS Abu-Surrah et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Cellular processing of platinum anticancer drugs
D Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes
KR Barnes et al.
CHEMISTRY & BIOLOGY (2004)
The β-glucuronyl-based prodrug strategy allows for its application on β-glucuronyl-platinum conjugates
RA Tromp et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS:: Indications of guanosine 5′-monophosphate O6-N7 chelation
U Warnke et al.
CHEMBIOCHEM (2004)
Pyropheophorbide 2-deoxyglucosamide: A new photosensitizer targeting glucose transporters
M Zhang et al.
BIOCONJUGATE CHEMISTRY (2003)
Toxicity of platinum compounds
JT Hartmann et al.
EXPERT OPINION ON PHARMACOTHERAPY (2003)
Platinum(IV) antitumour compounds: their bioinorganic chemistry
MD Hall et al.
COORDINATION CHEMISTRY REVIEWS (2002)
Mechanisms of resistance to cisplatin
M Kartalou et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2001)
Share Paper
